welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT02056808

condition: Duchenne Muscular Dystrophy

status: completed


The purpose of this study is to determine whether increasing doses of SMT C1100 are safe, well tolerated and achieve appropriate blood levels in patients with Duchenne Muscular Dystrophy (DMD).

intervention: SMT C1100

mechanism of action: Utophin modulator to promote utophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT02056808

last updated: November 14, 2020